Hepatitis B vaccine

Immunization-hepb3-of-one-year-old-children

Hepatitis B vaccine is a vaccine that prevents Hepatitis B, a serious liver infection caused by the Hepatitis B virus (HBV). This vaccine is a crucial tool in the global effort to reduce the incidence of hepatitis B, which can lead to chronic liver disease, cirrhosis, and liver cancer. The World Health Organization (WHO) recommends that all infants receive the hepatitis B vaccine as part of their routine immunizations.

Composition and Types

The hepatitis B vaccine is a recombinant vaccine, meaning it is produced through genetic engineering. It contains one of the viral envelope proteins, hepatitis B surface antigen (HBsAg), which is produced by yeast cells into which the genetic code for HBsAg has been inserted. There are several types of hepatitis B vaccines available, including monovalent vaccines, which only protect against hepatitis B, and combination vaccines, which protect against hepatitis B along with other diseases.

Efficacy and Schedule

The hepatitis B vaccine is highly effective in preventing hepatitis B virus infection. When the vaccine series is completed, more than 95% of healthy infants, children, and adolescents younger than 19 years of age develop adequate levels of seroprotection. The standard immunization schedule for the hepatitis B vaccine includes three doses, with the first dose typically given at birth, followed by the second and third doses at specified intervals.

Safety and Side Effects

The hepatitis B vaccine is considered safe for most people. Common side effects are mild and may include soreness at the injection site, low-grade fever, and tiredness. Serious side effects are rare but can occur, including allergic reactions.

Global Impact

The introduction of the hepatitis B vaccine has significantly reduced the number of new hepatitis B infections globally, particularly in countries with high rates of chronic HBV infection and among children born to HBV-infected mothers. The vaccine has also led to a decrease in the incidence of liver cancer and cirrhosis related to hepatitis B.

Controversies and Misconceptions

Despite its success, the hepatitis B vaccine has been subject to controversies and misconceptions, particularly regarding its safety and the timing of the first dose. However, extensive research and surveillance have consistently supported the vaccine's safety and efficacy.

Conclusion

The hepatitis B vaccine is a key component of public health efforts to combat liver disease and protect against the hepatitis B virus. Its widespread use has led to a significant decrease in new infections, chronic disease, and liver cancer associated with hepatitis B.

‎

---

Translate: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian